Cargando…

Diabetic Ketoacidosis Secondary to New Onset Type 1 Diabetes Mellitus Related to Pembrolizumab Therapy

Pembrolizumab is an immunoglobulin G4 (IgG4) monoclonal antibody used in the treatment of various types of cancers. Despite its efficacy, pembrolizumab does not specifically target cancer cells which often leads to common side effects seen in immunotherapies such as diarrhea, rash, fatigue, nausea,...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernandez, Andrea, Zeidan, Bassem, Desai, Parth, Frunzi, Johnathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957841/
https://www.ncbi.nlm.nih.gov/pubmed/33738153
http://dx.doi.org/10.7759/cureus.13302

Ejemplares similares